Working… Menu
Trial record 39 of 116 for:    Atenolol

Pharmacodynamic Influences of Candesartan, Atenolol, Hydrochlorothiazide and Drug Combinations in Hypertensive Patients.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00232882
Recruitment Status : Completed
First Posted : October 5, 2005
Last Update Posted : September 4, 2013
Ottawa Hospital Research Institute
Information provided by:
Institut de Recherches Cliniques de Montreal

Brief Summary:

Angiotensin receptor antagonists (ARA), beta-blockers and diuretics do not seem to confer equivalent cardiovascular protection in hard outcomes clinical trials (beta blockers inferior). These results may be explained by differences in their effects on sympathetic activity, oxidative stress, inflammation and renin angiotensin system activation.

How diuretic addition to first line therapy with ARAs and beta-blockers modulates neurohumoral and hemodynamic parameters is not well understood.

The main hypothesis of this study is that an ARA (candesartan) combined or not with a diuretic will not increase sympathetic activity as much as a beta blocker (atenolol). Secondary hypothesis are of similar nature but relate to hemodynamic parameters, oxidative stress markers, inflammatory markers, or the renin angiotensin system.

The main objective of this study is to assess and compare the effects of candesartan and atenolol and their combination with low dose diuretic therapy on the autonomic nervous system, hemodynamic parameters,on oxidative stress, on inflammatory markers, and on the renin-angiotensin system.

Protocol sponsored by Astra Zeneca canada

Condition or disease Intervention/treatment Phase
Hypertension Drug: Candesartan Thiazide Drug: Atenolol Thiazide Drug: Thiazide Candesartan Phase 4

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 86 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Neurohumoral and Oxidative Influences of Candesartan, Atenolol, Hydrochlorothiazide and Drug Combinations in Essential Hypertensive Patients.
Study Start Date : December 2003
Actual Primary Completion Date : April 2006
Actual Study Completion Date : April 2006

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: 1
Candesartan 16 mg for 4 weeks followed by candesartan 16 mg and hydrochlorothiazide 12.5 mg for 4 weeks
Drug: Candesartan Thiazide
Candesartan 16 mg for 4 weeks then added hydrochlorothiazide for 4 weeks

Active Comparator: 2
Atenolol 100 mg for 4 weeks followed by atenolol 100 mg + hydrochlorothiazide 12.5 mg for 4 weeks
Drug: Atenolol Thiazide
Atenolol 100 mg for 4 weeks followed by atenolol 100 mg + hydrochlorothiazide 12.5 mg for 4 weeks

Active Comparator: 3
Thiazide 25 mg for 4 weeks then added with Candesartan 16 mg
Drug: Thiazide Candesartan
Thiazide 25 mg for 4 weeks then added with Candesartan 16 mg

Primary Outcome Measures :
  1. Plasma norepinephrine [ Time Frame: June 2007 ]

Secondary Outcome Measures :
  1. 1. Seated blood pressure [ Time Frame: June 2007 ]
  2. 2. 24h ambulatory blood pressure [ Time Frame: June 2007 ]
  3. 3. Spectral analysis of heart rate (LF, HF, LF/HF) [ Time Frame: June 2007 ]
  4. 4. Plasma [ Time Frame: December 2007 ]
  5. a. renin [ Time Frame: december 2007 ]
  6. b. aldosterone [ Time Frame: December 2007 ]
  7. c. angiotensin II [ Time Frame: December 2007 ]
  8. d. catecholamines [ Time Frame: June 2007 ]
  9. e. 8-epi-isoprostane [ Time Frame: December 2007 ]
  10. f. Thiobarbituric acid reactive substances (TBARS) [ Time Frame: December 2007 ]
  11. g. nitrotyrosine [ Time Frame: December 2007 ]
  12. h. interleukin 18 [ Time Frame: December 2007 ]
  13. i. E selectine [ Time Frame: December 2007 ]
  14. j. C reactive protein [ Time Frame: December 2007 ]
  15. k. Insulin [ Time Frame: June 2007 ]
  16. l. glucose [ Time Frame: June 2007 ]
  17. 5. Urine [ Time Frame: June 2007 ]
  18. a. 8-epi-isoprostane [ Time Frame: December 2007 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Mild to moderate essential hypertension as defined by a morning mean DBP *90 mmHg and * 109 mm Hg, a mean SBP * 200 mm H for two consecutive visits (Visits 2 and 3) during the two-to-four week placebo run-in period,
  2. Ability to provide written informed consent.

Exclusion Criteria:

  1. Any woman not surgically sterile or menopausal who:

    1. has a positive urine pregnancy test at screening (Visit 1) or baseline (Visit 3)
    2. is breast feeding
  2. Pre-menopausal women (last menstruation < 1 year prior to start of run-in period) who:

    1. are not surgically sterile; and/or
    2. are of child-bearing potential and are NOT practicing acceptable means of birth control.
  3. Known or suspected secondary hypertension.
  4. Known reversible or non-reversible obstructive lung disease (e.g. asthma or COPD).
  5. Hepatic and/or renal dysfunction as defined by the following laboratory parameters:

    1. ALT or AST greater than 2.0 times the upper limit of reference range;
    2. Serum creatinine greater than 150 umol/L.
  6. Uncorrected volume depletion.
  7. NYHA functional class CHF III-IV (Refer to Appendices).
  8. Coronary heart disease needing pharmacological therapy.
  9. Stroke within the preceding six months.
  10. PTCA within the preceding three months.
  11. History of angioedema.
  12. Clinically significant sinus bradycardia below 55 beats/min. at randomization.
  13. Sustained ventricular tachycardia, atrial fibrillation, or other clinically relevant cardiac arrhythmias as determined by the clinical Investigator.
  14. Second or third degree AV block, left bundle branch block or any clinically relevant conduction abnormality as determined by the clinical Investigator.
  15. Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of aortic or mitral valve.
  16. Administration of digoxin.
  17. Patients with a fasting glucose > 7.0.
  18. Use of antihypertensive agents such as diuretics, ACE inhibitors, angiotensin II antagonists, *- blockers, *-blockers, calcium channel antagonists, direct vasodilators that cannot be stopped for the trial.
  19. Administration of other non-antihypertensive medications known to affect blood pressure (e.g., oral corticosteroids, MAO inhibitors, nitrates) at any time during the trial.
  20. Chronic use of salt substitutes containing potassium chloride; potassium supplements; extreme dietary restrictions.
  21. Uncorrected sodium depletion as defined by a serum sodium level less than 135 mEq/L.
  22. Clinically significant hyperkalemia as defined by serum potassium level greater than 5.2 mEq/L. Clinically significant hypokalemia as defined by serum potassium level less than 3.0 mEq/L.
  23. Patients receiving any investigational therapy within one month of signing the informed consent form.
  24. Known hypersensitivity to any component of candesartan, atenolol or hydrochlorothiazide.
  25. Any other clinical condition which, in the opinion of the principal Investigator, would not allow safe completion of the protocol and safe administration of trial medication.
  26. Known for allergy to sulfa or heparin
  27. Blood donation in the preceding 2 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00232882

Layout table for location information
Canada, Quebec
Institut de Recherches Cliniques de Montréal
Montréal, Quebec, Canada, H2W 1R7
Sponsors and Collaborators
Institut de Recherches Cliniques de Montreal
Ottawa Hospital Research Institute
Layout table for investigator information
Principal Investigator: Maxime Lamarre-Cliche, MD Institut de Recherches Cliniques de Montreal

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Maxime Lamarre-Cliche, Institut de Recherches Cliniques de Montreal Identifier: NCT00232882     History of Changes
Other Study ID Numbers: D2452L00003
First Posted: October 5, 2005    Key Record Dates
Last Update Posted: September 4, 2013
Last Verified: August 2013
Keywords provided by Institut de Recherches Cliniques de Montreal:
Blood pressure
Antihypertensive drugs
Clinical Pharmacology
Autonomic nervous system
Renin angiotensin system
Oxidative stress
Inflammatory markers
Additional relevant MeSH terms:
Layout table for MeSH terms
Vascular Diseases
Cardiovascular Diseases
Candesartan cilexetil
Sodium Chloride Symporter Inhibitors
Antihypertensive Agents
Natriuretic Agents
Physiological Effects of Drugs
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Anti-Arrhythmia Agents
Autonomic Agents
Peripheral Nervous System Agents
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents